Skip to content

EBIT at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
Pfizer logo
PfizerPFE
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s EBIT?
SELLAS Life Sciences Group, Inc. (SLS) reported EBIT of -$9.25M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s EBIT changed year-over-year?
SELLAS Life Sciences Group, Inc.'s EBIT decreased by 52.6% year-over-year, from -$6.06M to -$9.25M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s EBIT?
Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s EBIT has grown at a 2.8% compound annual growth rate (CAGR), from -$25.29M to -$28.27M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.